| Daniel Ethan Rubinstein, MD | |
|
2226 Nelson Hwy Ste 200, Chapel Hill, NC 27517-9638 | |
| (984) 974-2020 | |
| Not Available |
| Full Name | Daniel Ethan Rubinstein |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 9 Years |
| Location | 2226 Nelson Hwy Ste 200, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245625946 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
| Alamance Eye Care Pa | 6103722699 | 10 |
News Archive
Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.
The American Medical Group Association (AMGA) and Press Ganey Associates, Inc. today launched the healthcare industry's first survey designed to help accountable care organizations (ACOs) and high-performing health systems identify opportunities for improving both efficiency and quality. The tool, called the AMGA-Press Ganey Coordinated Care Solution, assesses a patient's entire episode of care and enables better management of population health to create positive patient outcomes and maximize shared savings.
According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.
The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.
› Verified 3 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.
The American Medical Group Association (AMGA) and Press Ganey Associates, Inc. today launched the healthcare industry's first survey designed to help accountable care organizations (ACOs) and high-performing health systems identify opportunities for improving both efficiency and quality. The tool, called the AMGA-Press Ganey Coordinated Care Solution, assesses a patient's entire episode of care and enables better management of population health to create positive patient outcomes and maximize shared savings.
According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.
The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.
› Verified 3 days ago
| Entity Name | Alamance Eye Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184641524 PECOS PAC ID: 6103722699 Enrollment ID: O20031208000222 |
News Archive
Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.
The American Medical Group Association (AMGA) and Press Ganey Associates, Inc. today launched the healthcare industry's first survey designed to help accountable care organizations (ACOs) and high-performing health systems identify opportunities for improving both efficiency and quality. The tool, called the AMGA-Press Ganey Coordinated Care Solution, assesses a patient's entire episode of care and enables better management of population health to create positive patient outcomes and maximize shared savings.
According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.
The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Ethan Rubinstein, MD 5221 Paramount Pkwy Ste 420, Morrisville, NC 27560-5491 Ph: () - | Daniel Ethan Rubinstein, MD 2226 Nelson Hwy Ste 200, Chapel Hill, NC 27517-9638 Ph: (984) 974-2020 |
News Archive
Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.
The American Medical Group Association (AMGA) and Press Ganey Associates, Inc. today launched the healthcare industry's first survey designed to help accountable care organizations (ACOs) and high-performing health systems identify opportunities for improving both efficiency and quality. The tool, called the AMGA-Press Ganey Coordinated Care Solution, assesses a patient's entire episode of care and enables better management of population health to create positive patient outcomes and maximize shared savings.
According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.
The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.
› Verified 3 days ago
Alexis Renee Pascoe, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 2226 Nelson Hwy Ste 200, Chapel Hill, NC 27517 Phone: 984-974-2020 | |
Dr. Paul Singer, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-4131 | |
Dr. Donald L Budenz, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5151 Bioinformatics, Cb 7040, Chapel Hill, NC 27599 Phone: 919-843-0297 | |
Christopher Jaeyon Hwang, MD, MPH Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2226 Nelson Hwy Ste 200, Chapel Hill, NC 27517 Phone: 984-974-2020 | |
Kathleen G Gordon, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: Unc Ch Department Of Ophthalmology, 130mason Farm Rd, 5151 Bioinformatics, Chapel Hill, NC 27599 Phone: 919-966-5296 Fax: 919-966-1908 | |
Dr. Rachel A Tesser, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 55 Vilcom Center Circle, Suite 110, Chapel Hill, NC 27514 Phone: 919-960-2720 Fax: 919-960-2721 | |
Steven Brent Flynn, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2226 Nelson Hwy Ste 200, Chapel Hill, NC 27517 Phone: 984-974-2020 |